Does Screening for Prostate Cancer with PSA Actually Save Men's Lives?
Apr 10, 2005, 09:08, Reviewed by: Dr.
|
|
Nevertheless, if caught early, men have a 100 percent, five-year survival rate - a surprisingly positive statistic compared to many other types of cancer. Clearly, early detection is a key to curing prostate cancer.
|
By American Association for Cancer Research,
Screening for prostate cancer with a PSA (prostate specific antigen) blood test, though routinely performed today in men middle-aged and older, remains a source of controversy. Questions continue about the test's overall effectiveness and its ability to actually save men's lives.
For example, elevated PSA levels don't necessarily equate with clinically significant prostate cancer. Some men faced with high test results, however, may have undergone unnecessary treatments, with debilitating side effects such as infertility, incontinence and impotence.
For others, a normal PSA has also be misleading. In these cases, undetected prostate cancer has grown and spread to other parts of the body, sometimes resulting in death.
Nevertheless, if caught early, men have a 100 percent, five-year survival rate - a surprisingly positive statistic compared to many other types of cancer. Clearly, early detection is a key to curing prostate cancer.
To put this controversy in perspective, a forum on "Controversies in the Screening and Early Detection of Prostate Cancer, will be held on Sunday, April 17, Room 204 Anaheim Convention Center at the 96th Annual Meeting of the American Association for Cancer Research.
The forum will feature two outspoken authorities in the field:
-- Otis W. Brawley, M.D., professor of Medicine, Hematology and Oncology at the Emory University School of Medicine and Professor of Epidemiology at the Emory Rollins School of Public Health, Atlanta, Ga.
-- Fritz H. Schroder, professor and chair of the Department of Urology, Erasmus University, Rotterdam, The Netherlands.
The session will be moderated by:
-- William G. Nelson V, M.D., Ph.D., professor in the departments of Oncology, Urology, Pharmacology and Molecular Sciences, Medicine, Pathology, and Radiation Oncology and Molecular Radiation Sciences, at Johns Hopkins University.
Members of the press are cordially invited to attend this session. 
- A forum on "Controversies in the Screening and Early Detection of Prostate Cancer", will be held on Sunday, April 17, Room 204 Anaheim Convention Center at the 96th Annual Meeting of the American Association for Cancer Research.
www.aacr.org
Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.
Contact: Warren R. Froelich
[email protected]
215-440-9300
American Association for Cancer Research
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
